Atara Biotherapeutics
NASDAQ: ATRAThousand Oaks, US · Incorporated in Delaware · 3 known investors
Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
Investors · 3
In the news
- Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigationnatlawreview.com · 2026
- How To Invest In Atara Biotherapeutics Inc Stock - ATRA Share Price Today & News | Stashstash.com · 2026
- ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - AOLaol.com · 2026
- ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - AOLaol.com · 2026
- Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - AOLaol.com · 2026
- Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress - BioSpacebiospace.com · 2026